Abbott reports two-year data for Xience V
US health care major Abbott Laboratories presented positive long-term data for its Xience V everlolimus eluting coronary stent system,a next-generation drug-eluting stent intended for use in the treatment of coronary artery disease,.at this year's EuroPCR conference in Barcelona, Spain.
The two-year results were fore the 1,002 patient, SPIRIT III, prospective, multi-center, randmized, single-blind, controlled, Phase III clinical trial comparing Xience V to fellow US company Boston Scientific's Taxus paclitaxel-eluting stent. The results showed that Abbott's device demonstrated a 45% reduction reduction in the risk of adverse cardiac events and a 32% reduction in the risk of target vessel failure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze